Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

scientific article

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1155/2015/809252
P932PMC publication ID4592919
P698PubMed publication ID26483978
P5875ResearchGate publication ID283049300

P2093author name stringLidia Nagae
Justin M Honce
Eric Nyberg
P2860cites workEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyQ24683776
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisQ84038259
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyQ84114256
Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosisQ84243572
Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patientsQ84337909
Natalizumab and central nervous system lymphoma: no clear associationQ84617830
Another complication of natalizumab treatment? Taking the challengeQ84617833
Natalizumab risk stratification: role of a two- step anti-JCV antibody assayQ84894409
Natalizumab dosage suspension: are we helping or hurting?Q84984557
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab TherapyQ85180313
PML in a patient treated with fumaric acidQ86649822
PML in a patient treated with dimethyl fumarate from a compounding pharmacyQ86649825
PML in a patient without severe lymphocytopenia receiving dimethyl fumarateQ87077624
Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?Q87127669
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathyQ87474221
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patientsQ87673522
Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumabQ26851341
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringQ28243804
Progressive multifocal leukoencephalopathy in a patient treated with natalizumabQ28255536
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisQ28255548
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's diseaseQ28255557
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisQ29616119
MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brainQ30049081
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.Q30583907
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease SectionQ30613846
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathyQ30689194
Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.Q30802654
Neuroimaging in posterior reversible encephalopathy syndromeQ30923275
Seizures and their outcome in progressive multifocal leukoencephalopathyQ31030491
Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment controlQ31050655
NatalizumabQ31081472
Neuro MR: principles.Q31121249
Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individualQ33193190
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative studyQ33443670
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption studyQ33571905
Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neuronsQ33834119
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisQ33893285
Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosisQ34089586
Progressive multifocal leukoencephalopathy: why gray and white matterQ34307762
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathyQ34324861
Outcome and survival of asymptomatic PML in natalizumab-treated MS patientsQ34562841
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.Q34621839
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapyQ34629205
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Q34803324
Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathyQ34993076
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.Q35215625
Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS.Q35450600
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.Q35609239
JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency.Q35870644
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?Q36544721
MRI aspects of progressive multifocal leukoencephalopathyQ36669261
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.Q37035618
Getting specific: monoclonal antibodies in multiple sclerosis.Q37165875
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionQ37180600
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patientsQ37206687
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesQ37714089
Fingolimod after natalizumab and the risk of short-term relapseQ37725909
Imaging manifestations of progressive multifocal leukoencephalopathyQ37745226
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patientsQ41069030
Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased TissuesQ41555932
MRI pattern in asymptomatic natalizumab-associated PML.Q41745436
Progressive multifocal leukoencephalopathy with selective involvement of the pyramidal tractsQ42165687
Progressive Multifocal Leukoencephalopathy in AIDS: Proton MR Spectroscopy Patterns of Asynchronous Lesions Confirmed by Serial Diffusion-Weighted Imaging and Apparent Diffusion Coefficient MappingQ42769448
Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patientsQ43720340
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyQ43765361
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?Q43897444
What to expect after natalizumab cessation in a real-life settingQ44012129
Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.Q44045441
Progressive multifocal leukoencephalopathy with gray matter involvementQ44132348
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodiesQ44417521
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisQ44825022
Allergic and nonallergic delayed infusion reactions during natalizumab therapyQ46599353
Melanoma complicating treatment with natalizumab for multiple sclerosisQ46767631
Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI.Q48216499
Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.Q48274489
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodQ48319736
Diagnosis of progressive multifocal leukoencephalopathy by computed tomographyQ48329153
Tumefactive multiple sclerosis lesions under fingolimod treatmentQ48350609
The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?Q48401612
Primary central nervous system lymphoma in a patient treated with natalizumabQ48444344
Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI studyQ48519323
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumabQ48588720
Progressive multifocal leukoencephalopathy limited to the brain stemQ48635790
Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopyQ48745765
Lesion extension detected by diffusion-weighted magnetic resonance imaging in progressive multifocal leukoencephalopathyQ48749920
MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.Q48829236
Progressive multifocal leukoencephalopathy: its pathological featuresQ48846642
Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.Q50802394
Herpes encephalitis during natalizumab treatment in multiple sclerosis.Q50984779
Central nervous system lymphoma associated with natalizumab.Q54390890
Acute disseminated encephalomyelitisQ56038008
Progressive multifocal leukoencephalopathyQ57112346
Primary central nervous system lymphoma in a patient treated with NatalizumabQ57580323
Association of melanoma and natalizumab therapy in the Italian MS population: a second case reportQ61657746
Lethal multiple sclerosis relapse after natalizumab withdrawalQ61709468
Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?Q61718801
AIDS- and non-AIDS-related PML association with distinct p53 polymorphismQ73461654
Progressive multifocal leukoencephalopathyQ73551630
Conventional and diffusion-weighted MRI in progressive multifocal leukoencephalopathy: new elements for identification and follow-upQ79190198
Diffusion-weighted imaging in patients with progressive multifocal leukoencephalopathyQ80831430
MRI in PML: bilateral medullary lesionsQ81208763
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patientsQ81301426
Infratentorial progressive multifocal leucoencephalopathy (PML) in a patient with SLE (2008: 4b)Q81472465
More on melanoma with transdifferentiationQ81568029
Natalizumab discontinuation: an increasingly tricky propositionQ82349582
Severe acute autoimmune hepatitis after natalizumab treatmentQ82877307
Clinically significant liver injury in patients treated with natalizumabQ82935643
Value of MRI as a surrogate marker for PML in natalizumab long-term therapyQ83363676
Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillanceQ83389204
Natalizumab-associated central nervous system lymphoma?--another patientQ83555059
P275copyright licenseCreative Commons Attribution 3.0 UnportedQ14947546
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectneuroimagingQ551875
multiple sclerosisQ8277
P304page(s)809252
P577publication date2015-01-01
P1433published inMultiple Sclerosis InternationalQ26853855
P1476titleNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
P478volume2015